Source: Siyu MedTech; Editor: ZHENG Siyu
Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
On December 19, 2023, the official website of the CSRC showed,SceneRay Co., Ltd. (hereinafter referred to as: Sceneray)The listing tutoring filing has been accepted by the CSRC, with Huatai United Securities as the tutoring institution and the Jiangsu CSRC as the dispatched institution.Coaching Filing MaterialsSceneray's IPO coaching plan is as follows:Sceneray was founded in 2011 and is aHomeAn innovative high-tech medical device company that integrates the research and development, production, and sales of deep brain stimulation systems., with full independent intellectual property rights, continuously developing new technologies and products. The company aims to become a high-end medical device company with international advanced technology and competitiveness, allowing more patients to benefit from the treatment effects of high-tech medical technology. According to official website information, the company has applied for over 380 patents cumulatively since its establishment, including 50 international patents.Sceneray boasts an executive team composed of core technology experts in deep brain stimulation systems, production experts, and company operations experts. These experts have accumulated extensive experience through many years of work in related fields both in China and abroad. Currently, the team members are primarily top graduates from prestigious universities such as Tsinghua, Peking, Fudan, and Jiaotong Universities.In terms of clinical trials, since 2012, Sceneray has collaborated with Professor Guodong Gao's team from the Air Force Medical University. Based on theoretical and technological innovations in addiction mechanisms, they have developed a drug rehabilitation brain-machine chip and a drug rehabilitation brain pacemaker system, aiming to solve the global challenge of high relapse rates after drug addiction. Currently, the single-center drug rehabilitation clinical trial has been completed, achieving breakthrough therapeutic effects. This result has been published in the international authoritative journal *Brain Stimulation*. Moreover, this product received expedited "Innovative Green Channel" approval from the National Medical Products Administration (NMPA) in 2017. The drug rehabilitation brain pacemaker is the world’s first medical device for treating drug addiction and mental disorders through multi-target combined modulation within the brain, placing it at the global forefront in this field.
Preliminary clinical trials suggest,Sceneray's Anti-Addiction Brain Stimulator Effectively Reduces Psychological Craving for Drugs in Addicts, Significantly Lowering Relapse Rates and Offering Hope for True Addiction Cessation.Currently, Sceneray's addiction-treating brain pacemaker is undergoing a rigorously standardized (prospective, multi-center, double-blind, randomized controlled) clinical trial across China to further validate its therapeutic efficacy.
Sceneray's Brain Pacemaker for Drug Rehabilitation Offers New Hope for Solving the Global Challenge of Addiction Treatment.# Main Product Display of the CompanyBased on the official website information,The company's core technologies include: applications for patients with Parkinson's disease"Bilateral Brain Asynchronous Stimulation"; Ensure that the electrode has no displacement in the brain."Intracranial Electrode Fixation Technology"; Making programmable pacemakers more flexible and convenient"Wireless High-Speed Non-Contact Programming Technology"; enabling remote interaction between doctors and patients"Remote Programming Follow-up Technology"; Achieving different frequency electrical stimulation pulses output in two functional areas of the brain with a single electrode"Bifunctional Area Combined Stimulation in the Brain"Technology.The core product information of the company is as follows:(1) SR1101 Rechargeable Implantable Deep Brain Stimulation Kit
The product hasSmall size, light weight, long lifespan, high charging efficiencyFeatures. Under commonly used parameters, the maximum charging interval can be up to 48 days. It can be charged daily or weekly. Patients can choose a fixed charging time based on their own charging habits. For most patients, charging for 5-10 minutes daily is sufficient to ensure regular use.(2) Dual-channel Implantable Deep Brain Stimulation Pulse Generator Kit
This pulse generator is a dual-channel implantable deep brain stimulation pulse generator, also known as"One-to-Two"Model, adopting stimulation chip design at the international forefront, achievesLeft-Right Brain Differential Frequency Programming, the polarity, voltage/current, pulse width, and frequency of each channel's stimulation contacts can be independently programmed, with options for both constant voltage and constant current stimulation modes.It also has the storage and selection of up to 13 sets of stimulation programs., providing patients with refined control options for periodic symptom fluctuations.(3) Implantable Deep Brain Stimulation Electrode Lead Kit
Stable support wire for accurate positioning; blunt puncture head, less likely to harm tissue.(4) Implantable Deep Brain Stimulation Extension Lead Kit
The extension lead isA component of the brain pacemaker system, used to transmit electrical pulse signals generated by the implantable neurostimulator to the 1200/1210/1211 type electrode leads.(5) Cranial Electrode Lock Kit
Craniotomy Electrode Lock with Global Patents, Craniotomy Ring 1.5mmThinner, more invisible, stronger fixation, and curvature design that better conforms to the skull., Electrode Lock, achieves immediate and automatic locking of the electrode. A force within 1N cannot pull the electrode, completely eliminating concerns about intraoperative electrode displacement.Detailed Display of Some Products:SR1101 Rechargeable Implantable Deep Brain Stimulation Kit
Product Features
1）Ingenious Battery Design:A more lightweight, slimmer, and streamlined human-centric design with a smaller volume, lighter weight, minimal implantation trauma, easy healing, and effectively reducing the patient's sense of foreignness.2）High charging efficiency:Under commonly used parameters, the maximum charging interval can be up to 48 days. Charging can be done daily or weekly, and patients can select a fixed charging time based on their own charging habits. For most patients, charging for 5-10 minutes daily is sufficient to ensure normal use. (For more details, refer to the actual programming parameters.)3）Up to 25 Years of Peace of Mind Guarantee:A 25-year warranty commitment means a lifetime guarantee with one implant for most patients. 4）Convenient Battery Check:The remaining battery power can be checked at any time via the charger/patient programmer/doctor programmer to ensure timely charging.The doctor’s programmer or patient’s programmer will trigger an alert 12 months before the rechargeable battery reaches its critical lifespan, allowing the doctor to schedule the surgery appropriately when connected to the neurostimulator.5）Safe Charging and Discharging Mode:No over-discharge phenomenon exists, and even if the patient has not charged for a long time, normal operation can be restored after recharging. Multiple temperature control measures strictly manage charging heat generation, and charging will automatically stop when body temperature exceeds the normal range.6）Sensitive Charging Detection:The implantation depth can reach 2cm, effectively ensuring the charging function.7）Portable Charging Backpack:Humanized design, ergonomic charging backpack makes charging more effortless for patients. 8）Dual-Channel Heterodyne Electrical Stimulation:According to the different symptoms on the left and right sides, completely different frequencies can be set to achieve better symptom control and treatment outcomes.9）13 Stimulation Program Groups:Achieve精细化 treatment plans, according to the patient's daily symptom fluctuations and different activity needs, doctors can set 13 groups of programs with completely different contacts, voltage, frequency, and pulse width.10）Wireless remote control:No wired connection required, liberating patients and making programming adjustments more convenient and objective without constraints. Intraoperative measurements can be performed without contact, significantly reducing the risk of intraoperative infection.11）Remote Control:Achieve remote programming between doctors and patients in different places, providing convenient and flexible programming time for both parties.(1) Patient-end Remote Control System
Sceneray Remote Programming System: Breaking Free from Spatial Constraints, Doctors Can Adjust Programming Parameters for Patients Thousands of Miles Away While Sitting in Their Offices.(2) Remote Control System - Doctor's End
Liberate Doctors, Freely Choose Programming Time(3) SR1421 Patient Programmer
The patient control software is directly installed on the patient's mobile phone, featuring an attractive interface, simple operation, and portability.(4) SR2114 External Charger Kit
Used to charge the battery of the rechargeable implantable neurostimulator (Model: SR1101) to extend the service life of the overcharged implantable neurostimulator.Detailed Display of Some Products:SR1632 Patient Programming SystemThe remote control technology is at the forefront of the international community. The remote system realizes the异地interaction between doctors and patients, making postoperative follow-up and remote control across space no longer a dream; the high-definition image transmission system presents the patient's Parkinson's symptoms in real time and accurately, no matter how far the doctor and patient are, it feels like face-to-face; the two-way call function ensures on-demand interaction between doctors and patients.
According to the inquiry, as of the publication date, the company has undergone 8 rounds of financing, with an amount reaching hundreds of millions of RMB, and the financing process has been stable.
As of the date of publication, the company has 387 patents. The details of the recent 9 patents are as follows:
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
